Our Mastery
Testimonial
- "Amazing success ratio in such uncertain market and paid service is very affordable ...Good job done by your team...keep it up guys."
-Venkat (Chennai)
Party Plot Owner - "I am trading in stock market since last 8 years; I have subscribed services from many advisory companies. Conclusion is that no one can provide 100% accuracy in this NSE market. But accuracy of intraday tips from this firm is the highest among all share tips companies" Rahul Varma (Mumbai)
Owner of an Insurance Firm - "I have taken free trial of intraday tips for 2 days and 80% call is profitable. Then I have subscribed paid membership for trading advice and now I am quite satisfied with services. Important thing is do not think more; Just trade what you are suggested" -Kevin Patel (Ahmedabad)
BDM at IT Company - "Made Good Profit in the Intraday, Jackpot Calls, F&o Tips. Overall Service is very good. Especially I like your Fast tips Sms Service & Exit Call System. Your tips have very good performance." -Manoj Arora (Delhi)
CEO of Real Estate Company
Dishman Pharmaceuticals and Chemicals Ltd share price today (on 21 March 2023).
We Provide Best stock tips for Dishman Pharmaceuticals and Chemicals Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Dishman Pharmaceuticals and Chemicals Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.
Get Free Stock Tips for Dishman Pharmaceuticals and Chemicals Ltd
BSE: 532526 | NSE: DISHMAN | ISIN: INE353G01020 Market Cap: [Rs.Cr.] 845 | Face Value: [Rs.] 2 Industry: Pharmaceuticals - Indian - Bulk Drugs
Dishman Pharmaceuticals and Chemicals Limited engages in the manufacture and marketing of bulk drugs, intermediates, quaternary compounds (quats), and specialty chemicals in India and internationally. The company involves in the manufacture and supply of a range of vitamins and chemical products, including vitamin D, vitamin D analogues, cholesterol, and lanolin related products for pharmaceutical, cosmetic, and related markets; and ammonium and phosphonium high purity solid Quats, as well as phosphoranes
Dishman Pharmaceuticals and Chemicals Ltd is a recognized supplier of cost-effective, high quality chemical services and products to the global pharmaceutical and chemical industry. They are involved in the manufacture of active pharmaceutical ingredients (API), API intermediates, quaternary ammonium compounds and fine chemicals. They are having their manufacturing facility at Ahmedabad in Gujarat. Dishman Pharmaceuticals and Chemicals Ltd was incorporated in the year 1983 as a research-oriented organization. The company set up their first manufacturing unit in Naroda for phase Transfer Catalysts. The company earned the status of 'Quat Company' by establishing themselves in the quat business. In the year 1995, the company formed a joint venture company with Sch tz & Co, Germany called as 'Schutz Dishman Biotech Private Ltd'. They manufacture Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution, for the European market.
In the year 1997, the company commenced their production in the unit I at Bavla. In the year 1998, the company established marketing subsidiaries Dishman Europe in London and Dishman USA in Middlesex New Jersey. In the year 2001, they signed the first contract manufacturing project. The company converted their entire Bavla facility into 100% Export oriented Unit in the year 2003. Also, they acquired Chemconserve BV in Netherland. In April 2004, the company incorporated a wholly owned subsidiary company namely Dishman International Trade (Shanghai) Co Ltd in China. Also, they incorporated Dishman FZE, a wholly owned subsidiary company at Jebel Ali Free Zone in Dubai in July 2004. During the year 2004-05, the company entered into an agreement with a leading British company NU SCAAN, for the development & manufacture of Bulk Actives for Neutraceutical products. The company acquired the business together with the technology basket pertaining to a group of speciality chemical products from C6, a UK company.
Also, they acquired a Manchester UK based Contract Research Company, Synprotec DCR Ltd., through their 100% wholly owned UK based subsidiary company Dishman Europe Ltd. During the year 2005-06, the company signed a Joint Venture and Shareholdes' Agreement with Arab Company for Drug Industries and Medical Appliances, Saudi Pharmaceutical Industries and Medical Appliances Corporation and Takamul Holding Company for Investments for manufacturing 20 API. The company formed a wholly owned subsidiary, Dishman Switzerland Ltd in Switzerland and through this company, they acquired Innovative Ozone Services Inc, a Switzerland based Contract Research Company.
In August 2006, the company acquired the business of Carbogen Amcis AG which is a Switzerland-based process research and low-volume, highvalue API and hypo Potency products manufacturing company. During the year 2006-07, the company formed a wholly owned subsidiary in Switzerland with the name Dishman Pharma Solution AG and an Indian wholly owned subsidiary, Dishman Infrastructure Ltd for the SEZ project. Also, they incorporated a wholly owned subsidiary company with the name Dishman Pharmaceuticals & Chemicals (Shanghai) Co Ltd at Shanghai Chemical Industry park in China. In April 2007, the company made a marketing joint venture with Azzurro Corporation of Japan, in the name of Dishman Japan Ltd for market the products and services of Dishman group as a whole in Japan and South Korea.
In October 2007, the company through their subsidiaries, acquired fine chemicals, vitamin D and vitamin D analogue business of Solvay Pharmaceuticals BV in Netherland. During the year 2007-08, the company formed an Indian wholly owned subsidiary, namely Carbogen Amcis (India) Ltd with an investment of Rs. 5 lakhs. In April 2008, they established a wholly owned subsidiary with the name Dishman Australasia Pty. Ltd in Australia. The new plant at Shanghai Chemical Zone is under construction. The commercial production is expected during the financial year 2008-09. The company has completed the installation of three API units at their Bavla facility anf the fourth one will commenced their operation during the financial year 2008-09. The company is in the process of setting up Pharmaceutical and Chemical SEZ near Bavla. For this, the company acquired 390 acres of land. The company is also in the process of building Asia's largest facility to manufacture cancer drugs and other high potency drugs at their Balva plant.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 8.34%, from INR 1,044.6 tens of millions to INR 1,131.72 tens of millions. Operating result increased from INR 216.01 tens of millions to INR 224.48 tens of millions which means 3.92% change. The results of the period decreased -30.22% reaching INR 56.76 tens of millions at the end of the period against INR 81.34 tens of millions last year. Return on equity (Net income/Total equity) went from 9.25% to 6.02%, the Return On Asset (Net income / Total Asset) went from 4.65% to 2.79% and the Net Profit Margin (Net Income/Net Sales) went from 7.79% to 5.02% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 140.82% compared to 98.83% of last year.
Nse Listed Companies with Live Charts
with live charts starting with that Alphabet.)
| A | B | C | D | E | F | G | H | I | J |
| K | L | M | N | O | P | Q | R | S | T |
| U | V | W | X | Y | Z |
